Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.

Oncology reports - 1 Mar 2012

Hofstetter Gerda, Berger Astrid, Bauer Eva-Maria, Schuster Eva, Wolf Andrea, Chamson Martina, Müller-Holzner Elisabeth, Reimer Daniel, Braicu Elena I, Sehouli Jalid, Ulmer Hanno, Cacsire Castillo-Tong Dan, Zeillinger Robert, Concin Nicole

Abstract excerpt

A single nucleotide polymorphism (SNP309) of MDM2 causes elevated MDM2 levels and an attenuation of p53 function. The aim of the present study was to examine the clinical relevance of the MDM2 SNP309 in ovarian cancer.MDM2 SNP309 genotype was analyzed in 198 patients with primary ovarian cancer. MDM2 expression was investigated using immunohistochemistry. A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterozygote

Share to Homozygote

Share to Ovarian Neoplasms

Share to Prognosis

Share to Proto-Oncogene Proteins c-mdm2

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 22134502
DOI: 10.3892/or.2011.1560

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.PMID 22134502Read ↗

Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma.Semantic proximity Read ↗

Association of breast cancer outcome with status of p53 and MDM2 SNP309.Semantic proximity Read ↗

Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.Semantic proximity Read ↗

Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival.Semantic proximity Read ↗

MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis.Semantic proximity Read ↗

MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies.Semantic proximity Read ↗

[Both somatic and germline genetics of the TP53-pathway influence ovarian cancer incidence and survival].Semantic proximity Read ↗

MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.Semantic proximity Read ↗

The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.Semantic proximity Read ↗

MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.Semantic proximity Read ↗

No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.Semantic proximity Read ↗

Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.